Apella Capital LLC Has $1.78 Million Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Apella Capital LLC increased its position in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 15.8% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 10,043 shares of the company’s stock after acquiring an additional 1,371 shares during the quarter. Apella Capital LLC’s holdings in Johnson & Johnson were worth $1,783,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Vanguard Group Inc. increased its holdings in Johnson & Johnson by 1.4% in the first quarter. Vanguard Group Inc. now owns 238,141,110 shares of the company’s stock valued at $42,205,749,000 after purchasing an additional 3,358,478 shares during the last quarter. BlackRock Inc. increased its holdings in shares of Johnson & Johnson by 0.4% in the first quarter. BlackRock Inc. now owns 200,799,189 shares of the company’s stock worth $35,587,638,000 after acquiring an additional 777,837 shares in the last quarter. State Street Corp increased its holdings in shares of Johnson & Johnson by 1.8% in the fourth quarter. State Street Corp now owns 144,677,639 shares of the company’s stock worth $24,750,004,000 after acquiring an additional 2,492,359 shares in the last quarter. Wellington Management Group LLP increased its holdings in shares of Johnson & Johnson by 0.8% in the first quarter. Wellington Management Group LLP now owns 32,772,594 shares of the company’s stock worth $5,808,286,000 after acquiring an additional 265,330 shares in the last quarter. Finally, Bank of New York Mellon Corp increased its holdings in shares of Johnson & Johnson by 1.6% in the first quarter. Bank of New York Mellon Corp now owns 32,070,396 shares of the company’s stock worth $5,683,837,000 after acquiring an additional 509,818 shares in the last quarter. Institutional investors own 68.59% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have issued reports on JNJ shares. Citigroup lowered their price target on Johnson & Johnson from $205.00 to $201.00 in a report on Wednesday, July 20th. Daiwa Capital Markets began coverage on Johnson & Johnson in a report on Wednesday, June 22nd. They issued an “outperform” rating for the company. Wells Fargo & Company increased their price objective on Johnson & Johnson from $190.00 to $195.00 and gave the stock an “overweight” rating in a report on Wednesday, July 13th. UBS Group decreased their price objective on Johnson & Johnson from $185.00 to $180.00 in a report on Thursday, July 21st. Finally, SVB Leerink decreased their price objective on Johnson & Johnson from $200.00 to $194.00 in a report on Wednesday, July 20th. Four equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Johnson & Johnson presently has an average rating of “Moderate Buy” and an average price target of $189.78.

Johnson & Johnson Stock Performance

Shares of NYSE JNJ opened at $167.60 on Monday. The stock has a 50 day moving average price of $168.96 and a 200 day moving average price of $174.29. Johnson & Johnson has a 52 week low of $155.72 and a 52 week high of $186.69. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.17 and a current ratio of 1.42. The stock has a market capitalization of $440.65 billion, a PE ratio of 24.40, a price-to-earnings-growth ratio of 2.99 and a beta of 0.61.

Johnson & Johnson (NYSE:JNJGet Rating) last issued its quarterly earnings results on Tuesday, July 19th. The company reported $2.59 EPS for the quarter, beating the consensus estimate of $2.57 by $0.02. Johnson & Johnson had a return on equity of 36.14% and a net margin of 19.21%. The firm had revenue of $24.02 billion during the quarter, compared to analysts’ expectations of $23.85 billion. During the same period in the prior year, the firm posted $2.48 earnings per share. The business’s quarterly revenue was up 3.0% compared to the same quarter last year. Analysts predict that Johnson & Johnson will post 10.7 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 6th. Stockholders of record on Tuesday, August 23rd were given a $1.13 dividend. The ex-dividend date was Monday, August 22nd. This represents a $4.52 dividend on an annualized basis and a dividend yield of 2.70%. Johnson & Johnson’s payout ratio is 65.79%.

Johnson & Johnson announced that its board has authorized a stock buyback program on Wednesday, September 14th that permits the company to buyback $5.00 billion in shares. This buyback authorization permits the company to purchase up to 1.2% of its shares through open market purchases. Shares buyback programs are generally an indication that the company’s management believes its stock is undervalued.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Featured Stories

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.